中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu

Vol.41 No.2 (292 in total) Feb. 2025

Theme Issue: Current Situation and Prospects of the Prevention and Treatment of Viral Hepatitis in China 

Chief Editor: WANG Yu

Chinese Foundation for Hepatitis Prevention and Treatment
Cover Content

 Previous Issue

Display Method:
Editorial
Public health management strategies： A pathway to eliminating viral hepatitis threats
Yu WANG
2025, 41(2): 201-204. DOI: 10.12449/JCH250201
Abstract(1868) HTML (43) PDF (534KB)(31)
Abstract:
This article reviews the results of the 2020 national epidemiological survey of chronic viral hepatitis and its public health significance and discusses the differences in standard treatment and management rates and public health management mode between chronic viral hepatitis and AIDS/tuberculosis....
Expert Forum
Advances and challenges in the treatment of chronic hepatitis B in China
Shan SHAN, Jidong JIA
2025, 41(2): 205-209. DOI: 10.12449/JCH250202
Abstract(1664) HTML (58) PDF (630KB)(54)
Abstract:
Since 1992， China has adopted a comprehensive strategy centered on universal infant hepatitis B vaccination. This approach has led to a significant reduction in the prevalence of hepatitis B surface antigen， particularly among younger age groups. Antiviral therapy not only improves the liver histolo...
Strategies and advances in hepatitis B vaccination in China
Lin TANG, Xia XU, Zemei ZHOU, Xiaoqi WANG, Jizhen LI, Zundong YIN, Fuzhen WANG
2025, 41(2): 210-215. DOI: 10.12449/JCH250203
Abstract(1988) HTML (37) PDF (1327KB)(27)
Abstract:
Hepatitis B is a major global public health issue. Through the implementation of comprehensive prevention and control strategies centered on hepatitis B vaccination， China has achieved remarkable progress in hepatitis B prevention and control， while there are still many issues and challenges. This a...
Advances， achievements， and challenges in action to eliminate hepatitis C as a public health threat in China
Jian LI, Zhongfu LIU
2025, 41(2): 216-220. DOI: 10.12449/JCH250204
Abstract(1865) HTML (41) PDF (630KB)(16)
Abstract:
In 2016， the World Health Organization proposed the vision of eliminating viral hepatitis as a public health threat by 2030， and since then， China has actively promoted the elimination of hepatitis C as a public health threat and has made great achievements by formulating policies， clarifying main t...
Research advances in the disease burden of viral hepatitis in China
Jian LI, Fuzhen WANG, Zhongdan CHEN, Jinlei QI, Ailing WANG, Fanghui ZHAO, Yuanyuan KONG, Jing SUN, Jiaqi KANG, Zundong YIN, Zhongfu LIU, Jidong JIA, Yu WANG
2025, 41(2): 221-227. DOI: 10.12449/JCH250205
Abstract(1134) HTML (37) PDF (2377KB)(29)
Abstract:
Over the past three decades， China has made significant progress in the prevention and control of viral hepatitis， and the incidence rates of new-onset pediatric hepatitis B virus infections and acute viral hepatitis in the population have reduced to a relatively low level； however， there is still a...
Working practices in eliminating the public health crisis caused by viral hepatitis in Hainan Province of China
Weihua LI, Changfu XIONG, Taifan CHEN, Bin HE, Dapeng YIN, Xuexia ZENG, Feng LIN, Biyu CHEN, Xiaomei ZENG, Biao WU, Juan JIANG, Lu ZHONG, Yuhui ZHANG
2025, 41(2): 228-233. DOI: 10.12449/JCH250206
Abstract(1872) HTML (42) PDF (1009KB)(17)
Abstract:
In 2022， Hainan provincial government launched the project for the prevention and control of viral hepatitis with the goals of a hepatitis B screening rate of 90%， a diagnostic rate of 90%， and a treatment rate of 80% among people aged 18 years and above by the year 2025， and the main intervention m...
Guideline
An excerpt of EASL clinical practice guidelines on the management of hepatocellular carcinoma（2024 edition）
Jiarui YANG, Jianxin JIANG
2025, 41(2): 234-239. DOI: 10.12449/JCH250207
Abstract(1968) HTML (47) PDF (609KB)(55)
Abstract:
Liver cancer is the third leading cause of cancer-related deaths worldwide， among which hepatocellular carcinoma （HCC） accounts for approximately 90% in primary liver cancer. The advances in diagnostic and treatment tools， along with a deeper understanding of their application， are transforming the ...
An excerpt of EASL clinical practice guidelines on liver transplantation （2024 edition）
Yanbin NI, Jiye ZHU
2025, 41(2): 240-246. DOI: 10.12449/JCH250208
Abstract(2015) HTML (44) PDF (636KB)(23)
Abstract:
In July 2024， the European Association for the Study of the Liver released the latest edition of EASL Clinical Practice Guidelines on liver transplantation. The purpose of the EASL guidelines presented here is not to cover all aspects of liver transplantation， but to focus on important advances sinc...
Fatty Liver Disease
Association of menopausal time and menopausal age with nonalcoholic fatty liver disease： An analysis based on a restricted cubic spline model
Chenlu ZHAO, Suping MA, Dongfang SHANG, Sutong LIU, Xiaoyan LIU, Yuanyuan ZHENG, Wenxia ZHAO
2025, 41(2): 247-253. DOI: 10.12449/JCH250209
Abstract(1984) HTML (45) PDF (1241KB)(21)
Abstract:
Objective To investigate the association of menopausal time and menopausal age with the risk of nonalcoholic fatty liver disease （NAFLD）， and to provide a basis for the early prevention and treatment of NAFLD in clinical practice. Methods Related data were collected from 373 postmenopausal women who...
Mechanism of 1，25（OH）2D3 improving liver inflammation in a rat model of nonalcoholic steatohepatitis induced by choline-deficient L-amino acid-defined diet
Haiyang ZHU, Jingshu CUI, Liu YANG, Mengting ZHOU, Jian TONG, Hongmei HAN
2025, 41(2): 254-262. DOI: 10.12449/JCH250210
Abstract(76) HTML (37) PDF (4284KB)(9)
Abstract:
Objective To investigate the effect of 1，25（OH）2D3 on the level of peroxisome proliferator-activated receptor-γ （PPAR-γ） in the liver， the phenotype of hepatic macrophages， and liver inflammation in a rat model of nonalcoholic steatohepatitis （NASH）， as well as the mechanism of 1，25（OH）2D3 improving...
Liver Fibrosis and Liver Cirrhosis
Value of different noninvasive diagnostic models in the diagnosis of esophageal and gastric varices with significant portal hypertension in compensated hepatitis B cirrhosis
Cheng LIU, Jiayi ZENG, Mengbing FANG, Zhiheng CHEN, Bei GUI, Fengming ZHAO, Jingkai YUAN, Chaozhen ZHANG, Meijie SHI, Yubao XIE, Xiaoling CHI, Huanming XIAO
2025, 41(2): 263-268. DOI: 10.12449/JCH250211
Abstract(1387) HTML (36) PDF (919KB)(10)
Abstract:
Objective To investigate the value of different noninvasive diagnostic models in the diagnosis of esophageal and gastric varices since there is a high risk of esophageal and gastric varices in patients with compensated hepatitis B cirrhosis and significant portal hypertension， and to provide a basis...
Influencing factors for recompensation in patients with decompensated hepatitis C cirrhosis
Danqing XU, Huan MU, Yingyuan ZHANG, Lixian CHANG, Yuanzhen WANG, Weikun LI, Zhijian DONG, Lihua ZHANG, Yijing CHENG, Li LIU
2025, 41(2): 269-276. DOI: 10.12449/JCH250212
Abstract(95) HTML (39) PDF (1211KB)(16)
Abstract:
Objective To investigate the influencing factors for recompensation in patients with decompensated hepatitis C cirrhosis， and to establish a predictive model. Methods A total of 217 patients who were diagnosed with decompensated hepatitis C cirrhosis and were admitted to The Third People’s Hospital ...
Impact of hepatocellular carcinoma on the prognosis of patients with liver cirrhosis undergoing emergency endoscopic therapy due to esophagogastric variceal bleeding
Xiaoqin ZHU, Na WEI, Yong XIAO, Baoping YU
2025, 41(2): 277-283. DOI: 10.12449/JCH250213
Abstract(1797) HTML (36) PDF (1277KB)(8)
Abstract:
Objective To investigate the impact of hepatocellular carcinoma （HCC） on the prognosis of patients with liver cirrhosis undergoing emergency endoscopic therapy for esophagogastric variceal bleeding， as well as independent influencing factors for the prognosis of liver cirrhosis patients without HCC ...
Liver Neoplasm
Characteristics of mitochondrial translational initiation factor 2 gene methylation and its association with the development of hepatocellular carcinoma
Huajie XIE, Kai CHANG, Yanyan WANG, Wanlin NA, Huan CAI, Xia LIU, Zhongyong JIANG, Zonghai HU, Yuan LIU
2025, 41(2): 284-291. DOI: 10.12449/JCH250214
Abstract(94) HTML (39) PDF (3131KB)(17)
Abstract:
Objective To investigate the characteristics of mitochondrial translational initiation factor 2 （MTIF2） gene methylation and its association with the development and progression of hepatocellular carcinoma （HCC）. Methods MethSurv and EWAS Data Hub were used to perform the standardized analysis and t...
Effect of gallic acid in increasing the chemosensitivity of hepatocellular carcinoma HepG2 cells to sorafenib
Baikun LIU, Zhiru WANG, Wenjing ZHAO
2025, 41(2): 292-299. DOI: 10.12449/JCH250215
Abstract(73) HTML (40) PDF (2972KB)(7)
Abstract:
Objective To investigate the chemosensitization effect of gallic acid （GA） combined with sorafenib （Sora） on hepatocellular carcinoma HepG2 cells and related mechanisms. Methods HepG2 cells were randomly divided into control group， GA group， Sora group， and GA+Sora group. CCK8 assay was used to meas...
Effect of Biejia Decoction Pill on aerobic glycolysis in hepatocellular carcinoma by regulating the protein kinase B/mammalian target of rapamycin signaling pathway
Qinwen TAN, Jingjing HUANG, Ruixi ZHONG, Yuanqin DU, Jian XU, Jinli NONG, Yujiao PENG
2025, 41(2): 300-306. DOI: 10.12449/JCH250216
Abstract(88) HTML (39) PDF (2065KB)(11)
Abstract:
Objective To investigate the inhibitory effect of Biejia Decoction Pill on the proliferation， migration， and aerobic glycolysis of hepatocellular carcinoma （HCC） using cell experiments， as well as related mechanisms. Methods Human liver cancer cell line Huh7 was selected， and Sprague-Dawley rats wer...
Other Liver Disease
Etiology spectrum， clinical features， and gene mutations of unexplained intrahepatic cholestasis： An analysis of 62 cases
Jialuo WANG, Yufeng ZHENG, Qingfang XIONG, Yongfeng YANG
2025, 41(2): 307-313. DOI: 10.12449/JCH250217
Abstract(2034) HTML (49) PDF (1558KB)(19)
Abstract:
Objective To investigate the etiology and clinical features of intrahepatic cholestasis and the diagnostic value of whole exome sequencing （WES） through a retrospective analysis of the medical history， pathological results， and gene sequencing data of 62 patients with unexplained intrahepatic choles...
Value of internal stratification analysis of abdominal wall muscles in predicting complications after orthotopic liver transplantation
Xin SHI, Chongxiao LIANG, Bei ZHANG, Jiping WANG
2025, 41(2): 314-321. DOI: 10.12449/JCH250218
Abstract(81) HTML (41) PDF (3265KB)(6)
Abstract:
Objective To divide the muscle into different subzones according to different density ranges using the stratified analysis on the basis of myosteatosis， and to investigate the effect of muscle density changes on complications （Clavien-Dindo grade ≥Ⅲ） after orthotopic liver transplantation （OLT）. Met...
Pancreatic Disease
Effect of laminin subunit α3 on epithelial-mesenchymal transition， invasion， and metastasis abilities of pancreatic cancer
Nenghong YANG, Likun REN, She TIAN, Min HAN, Zhu LI, Yuxiang ZHAO, Peng LIU
2025, 41(2): 322-332. DOI: 10.12449/JCH250219
Abstract(83) HTML (36) PDF (4709KB)(9)
Abstract:
Objective To investigate the effect of laminin subunit α3 （LAMA3） on the epithelial-mesenchymal transition （EMT）， invasion， and metastasis abilities of pancreatic cancer （PC）. Methods A comprehensive analysis was performed for tumor- and EMT-related databases to identify the EMT genes associated wit...
Case Report
Successful treatment of biliary fistula after Beger surgery by oral choledochoscopy-assisted percutaneous-endoscopic rendezvous technique： A case report
Yuxin WANG, Weigang GU, Zheng JIN, Xiaofeng ZHANG
2025, 41(2): 333-336. DOI: 10.12449/JCH250220
Abstract(84) HTML (34) PDF (4794KB)(6)
Abstract:
Duodenum-preserving pancreatic head resection， also known as Beger surgery， has a high incidence rate of bile duct injury after surgery， while the treatment modality for bile duct injury depends on the severity of the injury， and endoscopic therapy is often challenging in case of severe bile duct in...
Review
Association between Helicobacter pylori infection and hepatitis B virus-related liver diseases
Xiaonuo ZHAO, Suping MA, Zhun XIAO
2025, 41(2): 337-342. DOI: 10.12449/JCH250221
Abstract(1763) HTML (42) PDF (700KB)(21)
Abstract:
As a common infectious disease in China， chronic hepatitis B is hepatocyte injury and inflammatory necrosis due to immune response caused by hepatitis B virus （HBV）. Helicobacter pylori （Hp） is a Gram-negative helicobacter that colonizes and persists in the human gastric mucosa. In recent years， an ...
Molecular mechanisms of the interaction between hepatitis B virus infection and mitochondrial homeostasis
Xingtong LI, Taicheng ZHOU
2025, 41(2): 343-348. DOI: 10.12449/JCH250222
Abstract(95) HTML (48) PDF (856KB)(10)
Abstract:
Hepatitis B virus （HBV） infection can cause acute or chronic infection， while untreated patients can develop into liver cirrhosis or liver cancer， thereby leading to death. As one of the most important organelles of cells， the maintenance of the normal morphology and function of mitochondria is the ...
Research advances in traditional Chinese medicine for the treatment of hepatocellular carcinoma by regulating immune cells
Lijuan LONG, Zongyu WANG, Yali ZHAO, Chuanfu QIN, Hua QIU
2025, 41(2): 349-358. DOI: 10.12449/JCH250223
Abstract(96) HTML (53) PDF (1707KB)(19)
Abstract:
Hepatocellular carcinoma （HCC） is a common malignant tumor with a high mortality rate， an insidious onset， and complex pathological mechanisms. In the tumor microenvironment， tumor-promoting immune cells protect tumor cells from immune attacks， while dysfunction of anti-tumor immune cells causes the...
Advances in the diagnosis and treatment of hepatocellular carcinoma with bile duct tumor thrombus
Yuxiang GUO, Maosen WANG, Zhongyuan LIU, Xudong ZHANG, Pengfei MA, Xiangkun WANG, Renfeng LI
2025, 41(2): 359-364. DOI: 10.12449/JCH250224
Abstract(70) HTML (38) PDF (701KB)(14)
Abstract:
Hepatocellular carcinoma （HCC） with biliary duct tumor thrombus （BDTT） is currently not common in clinical practice and is easily misdiagnosed， and previously， it was often considered an advanced stage of the disease with a poor prognosis， making its treatment challenging. However， in-depth studies ...
New insights and prospects of drug-induced liver injury in the context of chronic cholestatic liver diseases
Simiao YU, Jiabo WANG, Xiaohe XIAO, Ruilin WANG
2025, 41(2): 365-369. DOI: 10.12449/JCH250225
Abstract(1999) HTML (37) PDF (598KB)(10)
Abstract:
Patients with chronic cholestatic liver diseases face numerous challenges in the detection， assessment， and management of suspected drug-induced liver injury （DILI）， and in particular， it is difficult to distinguish cholestatic DILI from the progression of underlying cholestatic liver diseases clini...
Construction and practice of the theory of “turbid toxin pathogenesis” and related prevention and treatment strategies for hepatic encephalopathy in traditional Chinese medicine/Zhuang medicine
Zhipeng WU, Yuqin ZHANG, Chun YAO, Minggang WANG, Na WANG, Mengru PENG, Ningfang MO, Yaqing ZHENG, Rongzhen ZHANG, Dewen MAO
2025, 41(2): 370-374. DOI: 10.12449/JCH250226
Abstract(1077) HTML (36) PDF (923KB)(6)
Abstract:
Hepatic encephalopathy is a difficult and critical disease with rapid progression and limited treatment methods in the field of liver disease， and it is urgently needed to make breakthroughs in its pathogenesis. Selection of appropriate prevention and treatment strategies is of great importance in d...
Role of alkaloid compounds in regulating chronic liver diseases
Yihui ZHENG, Jiahui WANG, Tiejian ZHAO, Xuelin DUAN, Lei WANG, Yang ZHENG, Shiquan YANG
2025, 41(2): 375-382. DOI: 10.12449/JCH250227
Abstract(74) HTML (36) PDF (1695KB)(7)
Abstract:
Chronic liver diseases with common causes including viral infections， alcohol abuse， and autoimmune diseases. Alkaloids， as a class of plant-derived compounds， have shown significant potential in regulating chronic liver diseases. Recent studies have shown that alkaloids are able to exert a therapeu...
Role of triggering receptor expressed on myeloid cells 2 in acute and chronic liver diseases
Xinyue CUI, Quanhao SUN, Lihong ZHENG, Haiqiang WANG
2025, 41(2): 383-388. DOI: 10.12449/JCH250228
Abstract(74) HTML (39) PDF (634KB)(7)
Abstract:
Triggering receptor expressed on myeloid cells 2 （TREM2） is expressed in resident non-parenchymal cells （NPCs） and is involved in various pathological processes including liver inflammation and immunoregulation. In recent years， TREM2 has attracted attention in the field of acute and chronic liver d...
Role of autophagy in treatment of paracetamol-induced liver injury
Guojing XING, Lifei WANG, Longlong LUO, Xiaofeng ZHENG, Chun GAO, Xiaohui YU, Jiucong ZHANG
2025, 41(2): 389-394. DOI: 10.12449/JCH250229
Abstract(73) HTML (37) PDF (1117KB)(10)
Abstract:
N-acetyl-p-aminophenol （APAP） is an antipyretic analgesic commonly used in clinical practice， and APAP overdose can cause severe liver injury and even death. In recent years， the incidence rate of APAP-induced liver injury （AILI） tends to increase， and it has become the second most common cause of l...
Research advances in autoimmune pancreatitis with pancreatic exocrine insufficiency
Xiang AO, Chenxiao LIU, Xianda ZHANG, Taojing RAN, Chunhua ZHOU, Duowu ZOU
2025, 41(2): 395-400. DOI: 10.12449/JCH250230
Abstract(81) HTML (38) PDF (1001KB)(7)
Abstract:
Autoimmune pancreatitis is a special type of chronic pancreatitis that can lead to abnormal pancreatic exocrine function in patients. Autoimmune pancreatitis comorbid with pancreatic exocrine insufficiency has a complex pathogenesis， and there is limited research on this topic， leading to the lack o...
Introduction of High - quality Articles in Foreign Journals
Hepatology｜Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages
2025, 41(2): 299-299. DOI: 10.12449/JCH2502.gwqkjpwzjj1
Abstract(64) HTML (35) PDF (898KB)(6)
Abstract:
Journal of Hepatology｜Protein phosphatase 6 regulates metabolic dysfunction-associated steatohepatitis via the mTORC1 pathway
2025, 41(2): 364-364. DOI: 10.12449/JCH2502.gwqkjpwzjj2
Abstract(73) HTML (29) PDF (900KB)(6)
Abstract:
Journal of Hepatology｜GRINA alleviates hepatic ischemia-reperfusion injury-induced apoptosis and ER-phagy by enhancing HRD1-mediated ATF6 ubiquitination
2025, 41(2): 382-382. DOI: 10.12449/JCH2502.gwqkjpwzjj3
Abstract(59) HTML (36) PDF (935KB)(6)
Abstract:
Liver International｜MASLD, At-Risk MASH and increased liver stiffness are associated with young adulthood obesity without residual risk after losing obesity
2025, 41(2): 400-400. DOI: 10.12449/JCH2502.gwqkjpwzjj4
Abstract(54) HTML (30) PDF (1294KB)(5)
Abstract:
Acknowledgements
Current reviewers
2025, 41(2): 306-306. DOI: 10.12449/JCH2502.zhixie
Abstract(43) HTML (25) PDF (910KB)(3)
Abstract:
    

The first journal specializing in hepatobiliary and pancreatic diseases in China

Supervisor：Ministry of Education of the People's Republic of China

Sponsor：Jilin University

Academic Support: Chinese Society of Hepatology，Chinese Medical Association

Address: 461 Xinjiang Road, Changchun

Submit：0431-88782044

Peer review：0431-88783542

Email：lcgdb@vip.163.com

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

YesterdayIP[2720]YesterdayPV[5120]TodayIP[3384]TodayPV[6221]Online[146]

Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd